TMEM200B and non-small cell lung carcinoma: Although recent clinical trials have shown a correlation between tTMB-High and improved clinical outcomes in advanced NSCLC patients receiving ICIs, up to 30% of advanced NSCLC patients are unlikely to have sufficient tissue specimens for biomarker analysis during diagnosis (13–15).